Get the Stockscreener App
50.24
2.85%
1.39
After Hours:
50.24
Haemonetics Corp stock is traded at $50.24, with a volume of 1.07M.
It is up +2.85% in the last 24 hours and down -3.75% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$48.85
Open:
$49.07
24h Volume:
1.07M
Relative Volume:
1.13
Market Cap:
$2.42B
Revenue:
$1.36B
Net Income/Loss:
$123.81M
P/E Ratio:
20.85
EPS:
2.41
Net Cash Flow:
$20.35M
1W Performance:
+1.39%
1M Performance:
-3.75%
6M Performance:
-16.32%
1Y Performance:
-32.99%
1-Day Range:
$48.62
$50.49
1-Week Range:
$48.17
$51.37
52-Week Range:
$47.31
$94.98
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
50.24 | 2.35B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ABT
Abbott Laboratories
|
131.38 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
94.95 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.92 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.58 | 122.43B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.95 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Dentsply Sirona, Acadia Healthcare, and Haemonetics Stocks Trade Down, What You Need To Know - Yahoo Finance
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025 - Yahoo Finance
Haemonetics (NYSE:HAE) Receives Hold (C-) Rating from Weiss Ratings - MarketBeat
FY2028 EPS Estimates for Haemonetics Cut by Zacks Research - MarketBeat
Q1 EPS Estimates for Haemonetics Cut by Zacks Research - Defense World
Citigroup Lowers Price Target for Haemonetics (HAE) to $64.00 | - GuruFocus
Q1 EPS Estimates for Haemonetics Decreased by Zacks Research - MarketBeat
How Haemonetics Corporation stock responds to bond marketMarket Movement Recap & Low Risk Investment Opportunities - newser.com
Hunter Perkins Capital Management LLC Acquires Shares of 7,100 Haemonetics Corporation $HAE - MarketBeat
Is Haemonetics Corporation HAZ a good long term investmentTechnical Resistance Breaks & High Return Trading Plans - earlytimes.in
What analysts say about Launch Two Acquisition Corp stockEarnings Per Share Trends & Affordable Investment Portfolio - earlytimes.in
Why Haemonetics Corporation (HAZ) stock stays on buy listsJuly 2025 Rallies & Safe Capital Allocation Plans - newser.com
Can trapped investors hope for a rebound in Haemonetics CorporationRate Hike & Growth Oriented Trading Recommendations - newser.com
What the Recent FDA Plasma Guidance Means for Haemonetics Investors in 2025 - simplywall.st
Haemonetics (NYSE:HAE) Reaches New 12-Month LowHere's What Happened - MarketBeat
How to forecast Haemonetics Corporation trends using time seriesTrade Exit Summary & Free Safe Entry Trade Signal Reports - newser.com
Is Haemonetics (HAE) Undervalued? A Fresh Look at the Company’s Current Valuation - simplywall.st
How Haemonetics Corporation (HAZ) stock reacts to weak economyQuarterly Market Review & Daily Profit Maximizing Trade Tips - newser.com
Why analysts recommend Haemonetics Corporation (HAZ) stockJuly 2025 Outlook & Fast Entry High Yield Tips - newser.com
Is Haemonetics Corporation (HAZ) stock a buy before earnings resultsMarket Growth Summary & Capital Protection Trading Alerts - newser.com
Published on: 2025-10-01 03:46:03 - newser.com
What technical patterns form on Haemonetics Corporation stock chartsGap Down & Entry and Exit Point Strategies - newser.com
Haemonetics Corporation stock volume spike explained2025 Market Overview & AI Enhanced Execution Alerts - newser.com
Exit strategy if you’re trapped in Haemonetics Corporation2025 Trading Recap & Capital Efficiency Focused Ideas - newser.com
How to use Fibonacci retracement on Haemonetics Corporation2025 Key Lessons & AI Driven Stock Price Forecasts - newser.com
Published on: 2025-09-27 20:13:44 - newser.com
Real time breakdown of Haemonetics Corporation stock performanceBuy Signal & Verified Short-Term Plans - newser.com
Published on: 2025-09-26 12:26:45 - newser.com
Will Haemonetics Corporation stock keep outperforming rivalsWeekly Investment Summary & Growth Oriented Trading Recommendations - The British Mountaineering Council
Bausch + Lomb, Enovis, and Haemonetics Shares Plummet, What You Need To Know - Yahoo Finance
Haemonetics (NYSE:HAE) Given Outperform Rating at Barrington Research - Defense World
Haemonetics (NYSE:HAE) Earns "Outperform" Rating from Barrington Research - MarketBeat
Haemonetics (HAE) Maintains Rating with Barrington Research | HA - GuruFocus
Is Haemonetics Corporation building a consolidation baseEarnings Recap Report & AI Based Buy and Sell Signals - newser.com
Visual analytics tools that track Haemonetics Corporation performanceJuly 2025 Price Swings & Accurate Intraday Trading Signals - newser.com
Combining machine learning predictions for Haemonetics CorporationM&A Rumor & AI Enhanced Market Trend Forecasts - newser.com
Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Harbor Capital Advisors Inc. Lowers Stake in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):